来自[具体来源未提及]的蛋白酶抑制剂可抑制新型冠状病毒（SARS-CoV-2）的复制。
Protease inhibitors from impair SARS-CoV-2 replication .
作者信息
Guimarães Santana Brenda Conceição, de Almeida Marques Daisymara Priscila, Dos Santos Freitas Andria, Ferreira Monaliza Macêdo, de Sousa Lopes Danielle, Bagno Flávia Fonseca, Guimarães da Fonseca Flávio, Dos Reis Jordana Grazziela Alves Coelho, Oliveira Mendes Tiago Antônio de, Santos Jane Lima Dos, Pirovani Carlos Priminho
机构信息
Laboratório de Proteômica, Departamento de Ciências Biológicas, Universidade Estadual de Santa Cruz, Ilhéus, BA, Brazil.
Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
出版信息
Heliyon. 2023 May;9(5):e15860. doi: 10.1016/j.heliyon.2023.e15860. Epub 2023 May 3.
SARS-CoV-2 is a newly emerging virus from the family that has already infected over 700 million people worldwide and killed over 6 million. This virus uses protease molecules to replicate and infect the host, which makes these molecules targets for therapeutic substances to eliminate the virus and treat infected people. Through the protein-protein molecular docking approach, we detected two cystatins from TcCYS3 and TcCYS4, described as papain-like protease inhibitors. These inhibitors decreased SARS-CoV-2 genomic copies without toxicity to Vero cells. There is a need to perform comprehensive studies in relevant animal models and to investigate the action mechanisms of protease inhibitors from that control the replication of SARS-CoV-2 in human cells.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是一种新出现的病毒，来自该病毒家族，已在全球感染超过7亿人，导致超过600万人死亡。这种病毒利用蛋白酶分子进行复制并感染宿主，这使得这些分子成为治疗物质消除病毒和治疗感染者的靶点。通过蛋白质-蛋白质分子对接方法，我们从TcCYS3和TcCYS4中检测到两种半胱氨酸蛋白酶抑制剂，被描述为木瓜蛋白酶样蛋白酶抑制剂。这些抑制剂可降低SARS-CoV-2基因组拷贝数，且对Vero细胞无毒。有必要在相关动物模型中进行全面研究，并研究来自[具体来源未明确]的蛋白酶抑制剂控制SARS-CoV-2在人类细胞中复制的作用机制。
Zotero 插件